AU Patent

AU2013201986B2 — Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients

Assigned to Intermune Inc · Expires 2014-08-07 · 12y expired

What this patent protects

A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are 5 methods of treating fibrotic condit…

USPTO Abstract

A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are 5 methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013201986B2
Jurisdiction
AU
Classification
—
Expires
2014-08-07
Drug substance claim
No
Drug product claim
No
Assignee
Intermune Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.